Parallel treatment study with 4 arms no masking.
This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.
Tirzepatide versus Insulin Lispro 3 times daily
Study Length: 26 Weeks
Target Age/Sex: over 18 years, Male and Female
Participants will receive at no cost: study product, study materials and study-specific procedures